

SHUKRA PHARMACEUTICALS LTD.

28th March, 2024

To,
The Department of Corporate Services
BSE Limited
Ground Floor, P. J. Tower,
Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir,

Sub: - Outcome of Independent Directors Meeting Dated March 28, 2024

Ref: - Regulation 30 of the SEBI (LODR) Regulations, 2015

This is to inform you that pursuant to Regulation 25(3) of the Securities and Exchange Board of India (LODR) Regulations, 2015 read with Schedule IV of the Companies Act, 2013, a separate meeting of the Independent Directors of the Company for the Financial Year 2023-24 was held today, i.e., on Thursday, 28th March, 2024 at the registered office of the company wherein the Independent Directors present at the meeting, *inter-alia*, transacted the following business:

- a) reviewed the performance of non-independent directors and the board of directors as a whole;
- b) reviewed the performance of the chairperson of the listed entity, taking into account the views of executive directors and non-executive directors;
- c) assessed the quality, quantity and timeliness of flow of information between the management of the listed entity and the board of directors that is necessary for the board of directors to effectively and reasonably perform their duties

Please take the same on your information and record.

The Meeting of Independent Directors was Commenced at 3.45 P.M. and concluded at 4.30 P.M.

Thanking you, Yours Faithfully,

For Shukra Pharmaceuticals Limited

BHOOMIBEN PATEL

Director

DIN: 08316893

CIN: L24231GJ1993PLC019079